<code id='767255B0EF'></code><style id='767255B0EF'></style>
    • <acronym id='767255B0EF'></acronym>
      <center id='767255B0EF'><center id='767255B0EF'><tfoot id='767255B0EF'></tfoot></center><abbr id='767255B0EF'><dir id='767255B0EF'><tfoot id='767255B0EF'></tfoot><noframes id='767255B0EF'>

    • <optgroup id='767255B0EF'><strike id='767255B0EF'><sup id='767255B0EF'></sup></strike><code id='767255B0EF'></code></optgroup>
        1. <b id='767255B0EF'><label id='767255B0EF'><select id='767255B0EF'><dt id='767255B0EF'><span id='767255B0EF'></span></dt></select></label></b><u id='767255B0EF'></u>
          <i id='767255B0EF'><strike id='767255B0EF'><tt id='767255B0EF'><pre id='767255B0EF'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:7772
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In